Dolan Oliver
Known title: Senior Vice President, FinanceCIK: 0002053835
Associated companies
Transaction History
| KRRO | ▼ Sell | Open Market | 5 | $69 | 9/11/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 6 | $82 | 9/9/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 7,347 | $99K | 9/8/2026 | View on chart |
| KRRO | ▲ Buy | Grant | 5,500 | $0 | 7/15/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 3,383 | $37K | 6/16/2026 | View on chart |
| KRRO | ▲ Buy | Grant | 21,482 | $0 | 12/15/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.